HYD1 is a D–amino acid peptide that was previously shown to inhibit adhesion of prostate
cancer cells to the extracellular matrix. In this study, we show that in addition to inhibiting …

Aurora-A is a mitotic kinase that regulates mitotic spindle formation and segregation. In
multiple myeloma (MM), high Aurora-A gene expression has been correlated with …

The Hsp90 inhibitor 17DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin) is
currently undergoing clinical trials as an antitumor drug. We show here that treatment of …

Integrins and downstream signaling kinases, such as proline-rich tyrosine kinase 2 (PYK2)
and focal adhesion kinase (FAK), are important for sensing cell adhesion to the extracellular …

Constitutive activation of the transcription factor STAT3 contributes to the pathogenesis of
many cancers, including multiple myeloma (MM). Since STAT3 is dispensable in most …

Abnormal activation of hypoxia-inducible factor-1 (HIF-1), one of the most important
transcription factors for the adaptation of cells to hypoxia, is frequently observed in …

Bortezomib (BTZ), a selective proteasome inhibitor, exhibits a significant efficacy in the
therapy of multiple myeloma (MM) partly through triggering endoplasmic reticulum (ER) …

Multiple myeloma is still an incurable disease; therefore, new therapeutics are urgently
needed. A771726 is the active metabolite of the immunosuppressive drug leflunomide …

Background 5-aminolevulinic acid-mediated PDT (ALA-PDT) has been used in a variety of
skin diseases including cSCC (cutaneous squamous cell carcinoma). Halofuginone (HL) is …

Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the oral and
maxillofacial regions, with a high rate of metastasis. Cancer-associated fibroblasts (CAFs) …